Provided by Tiger Trade Technology Pte. Ltd.

Maze Therapeutics

26.26
-0.2750-1.04%
Volume:149.61K
Turnover:3.98M
Market Cap:1.45B
PE:-10.43
High:27.44
Open:26.49
Low:26.00
Close:26.53
52wk High:53.65
52wk Low:14.16
Shares:55.25M
Float Shares:37.25M
Volume Ratio:0.68
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5172
EPS(LYR):-3.0510
ROE:-37.35%
ROA:-21.79%
PB:3.20
PE(LYR):-8.61

Loading ...

Stock Track | Maze Therapeutics Soars 5.65% Intraday on Positive Analyst Ratings and Target Price Increases

Stock Track
·
Mar 31

J.P. Morgan Sticks to Its Buy Rating for Maze Therapeutics, Inc. (MAZE)

TIPRANKS
·
Mar 31

U.S. RESEARCH ROUNDUP-Dutch Bros, Phreesia, Starbucks

Reuters
·
Mar 31

Maze Therapeutics Inc : JP Morgan Raises Target Price to $58 From $52

THOMSON REUTERS
·
Mar 31

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 30

Assessing Maze Therapeutics (MAZE) Valuation After Recent Share Price Weakness And Rich Price To Book Ratio

Simply Wall St.
·
Mar 30

Maze Therapeutics, Inc. (MAZE) Gets a Buy from LifeSci Capital

TIPRANKS
·
Mar 28

Stock Track | Maze Therapeutics Soars 5.17% Intraday on Analyst Insights

Stock Track
·
Mar 26

Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Maze Therapeutics, Inc. (MAZE) and Compass Therapeutics (CMPX)

TIPRANKS
·
Mar 26

BUZZ-U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings

Reuters
·
Mar 26

Top Midday Decliners

MT Newswires Live
·
Mar 26

Maze Therapeutics share sell-off an ‘overreaction,’ says Raymond James

TIPRANKS
·
Mar 25

Maze Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 25

Maze Therapeutics falls -33.2%

TIPRANKS
·
Mar 25

Leerink remains bullish on Maze, says Vertex comparison ‘apples to oranges’

TIPRANKS
·
Mar 25

Maze Therapeutics releases HORIZON MZE829 topline data call presentation; cash runway extends into 2028

Reuters
·
Mar 25

Maze Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $110 From $60

THOMSON REUTERS
·
Mar 25

Maze Therapeutics Shares Plunge 21% Premarket After Q4 Results

THOMSON REUTERS
·
Mar 25

Maze Therapeutics Says Phase 2 Trial of Kidney Disease Therapy Shows Over 35% Protein Marker Reduction

MT Newswires Live
·
Mar 25

BUZZ-U.S. STOCKS ON THE MOVE-Arm, Destiny Tech100, Terns Pharma

Reuters
·
Mar 25